Companies: 10,795·Total market cap: $144.5T
Gemina Laboratories Ltd.

Gemina Laboratories Ltd.

GLABFOTCHealthcare● Active
$0.05
+$0.00(+0.00%)
Market Cap$3828545
P/E Ratio
52W High$0.6269
52W Low$0.0375
Overview

Gemina Laboratories Ltd. (GLABF) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · GLABF · as of Jun 9, 2026

Key Statistics

EPS (TTM)glabf eps ttm · glabf earnings per shareEarnings history
PE Ratio (TTM)glabf pe ratio ttm · glabf price to earningsPE Ratio deep dive
Revenue (TTM)glabf revenue ttm · glabf annual revenueFull revenue history
Dividend YieldNo Dividenddoes glabf pay dividends · glabf dividend yieldDividend history
Shares Outstandingglabf shares outstanding · glabf floatShares outstanding history
Next EarningsTBAglabf earnings date · glabf next earningsEarnings history

About Gemina Laboratories Ltd.

CEORobert Crandall Greene
IPO DateMar 29, 2022
Employees6
CountryCA

Gemina Laboratories Ltd. is a Canadian biotechnology enterprise primarily focused on the investigation, creation, and commercialization of in vitro diagnostic solutions. The firm's innovation extends …

what is gemina laboratories ltd. · glabf stock overview · gemina laboratories ltd. company profile · who is gemina laboratories ltd. ceo · glabf OTC · gemina laboratories ltd. headquarters · gemina laboratories ltd. business segments

About Stock Overview & Key Data

Gemina Laboratories Ltd. (GLABF) is a Healthcare company in the Biotechnology industry, listed on OTC since Mar 29, 2022. As of the latest trading session, GLABF stock price is $0.05, with a market capitalization of $3.8M. The stock has returned — over the past 12 months and — year-to-date.

Frequently Asked Questions

As of the latest trading session, Gemina Laboratories Ltd. (GLABF) stock price is $0.05. The stock is traded on OTC under the ticker symbol GLABF. The 52-week range is $0.04 – $0.63.

GLABF stock priceGLABF quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice